文献速递胸部肿瘤放疗放疗物理与技术

肺癌立体定向放疗症状性放射性肺炎多因素预测模型开发

Development of a multifactorial prediction model for symptomatic radiation pneumonitis in lung cancer patients undergoing stereotactic body radiotherapy.
PubMed 文献 · Radiat Oncol · 2026-05-22

该回顾性研究纳入120例接受SBRT的原发性肺癌患者,基于V5、LPR和OT构建多因素logistic回归模型预测症状性放射性肺炎,交叉验证AUC为0.875、测试集AUC为0.921,并据此建立三层风险分层系统。

要点

  • SRP总体发生率为43.3%(52/120)。
  • 最终模型纳入肺V5、LPR和OT三个独立预测因子,LPR效应最强。
  • 模型预测概率将患者分为低危(P<0.3)、中危(0.3≤P≤0.7)和高危(P>0.7)。

核心结论

  • 整合低剂量参数V5、新型体积比LPR和其他既往治疗史OT可构建稳健且简洁的SRP预测模型。
  • 基于预测概率的三层风险评分可为个体化咨询和治疗计划制定提供实用工具,但尚需前瞻性验证。

研究设计与样本

  • 回顾性分析纳入2019年1月至2024年12月接受SBRT的120例原发性肺癌患者,评估24项人口学、临床、体积和剂量学参数。
  • 采用三步统计框架:单因素分析筛选候选预测因子(p<0.05),Spearman相关和VIF分析排除共线性,构建多因素logistic回归模型并采用SMOTE处理类别不平衡。
  • 模型通过5折交叉验证和独立测试集验证,性能评估使用AUC、准确率、校准图和Brier评分。

主要发现

  • SRP总体发生率为43.3%(52/120)。
  • 单因素分析识别12个与SRP显著相关的变量(p<0.05),涵盖所有DVH参数(V5-V30、MLD)、靶区体积和其他既往治疗(OT)。
  • 共线性分析后保留肺V5(%)、肺与PTV比值(LPR)、OT和TPS四个候选变量进入多因素建模。
  • 多因素logistic回归确认V5(OR=1.113每%;p<0.01)、LPR(OR=0.959每单位;p<0.01)和OT(OR=2.672;p<0.01)为显著独立预测因子,LPR效应最强。
  • 最终模型交叉验证AUC为0.875、测试集AUC为0.921,校准良好(Brier评分=0.13)。

关键数值与推荐

  • 基于预测概率将患者分为三层风险组:低危P<0.3、中危0.3≤P≤0.7、高危P>0.7。
  • 单因素分析统计显著性定义为p<0.05。

临床怎么用

  • 可利用V5、LPR和OT在治疗前评估SRP风险,辅助个体化患者咨询和治疗计划制定。
  • 根据模型预测概率将患者分为低、中、高危三层,便于临床风险分层管理。

局限性

  • 本研究为回顾性分析,样本量120例,结论需进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Symptomatic radiation pneumonitis (SRP) remains a clinically significant toxicity following lung stereotactic body radiotherapy (SBRT). However, existing prediction models have seen limited clinical adoption, as they tend to be either too complex for routine application or too simplistic for reliable risk stratification. This study aimed to develop a robust prediction model by integrating key dosimetric, volumetric, and clinical variables, and to translate this model into a practical risk score to support individualized pretreatment assessment. MATERIALS AND METHODS: This retrospective analysis included 120 patients with primary lung cancer treated with SBRT between January 2019 and December 2024. A total of 24 demographic, clinical, volumetric, and dosimetric parameters were evaluated. The primary endpoint was the development of SRP. A three-step statistical framework was employed for model development. First, candidate predictors were identified using univariate analysis (Mann-Whitney U test for continuous variables and Chi-square test for categorical variables), with statistical significance defined as p < 0.05. Second, this set of variables was refined through multicollinearity diagnosis using Spearman correlation and variance inflation factor (VIF) analysis to ensure predictor independence. Third, an optimal multivariate logistic regression model was constructed, incorporating the synthetic minority over-sampling technique (SMOTE) to address class imbalance, and validated using 5-fold cross-validation and an independent test set. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), accuracy, calibration plots, and the Brier score. A practical risk stratification system was subsequently developed based on the model's predicted probabilities. RESULTS: The overall incidence of SRP was 43.3% (52/120). Univariate analysis identified 12 variables significantly associated with SRP (p < 0.05), encompassing all dose-volume histogram (DVH) parameters (V5-V30, MLD), target volumes, and other prior therapy (OT). Following multicollinearity analysis, four independent candidates-lung V5 (%), Lung-to-PTV Ratio (LPR), OT, and treatment planning system (TPS)-were retained for multivariate modeling. Multivariate logistic regression confirmed V5 (OR = 1.113 per %; p < 0.01), LPR (OR = 0.959 per unit; p < 0.01), and OT (OR = 2.672; p < 0.01) as significant independent predictors, with LPR exhibiting the strongest effect. The final model demonstrated excellent discriminative performance, achieving a cross-validated AUC of 0.875 and a test set AUC of 0.921, along with good calibration (Brier score = 0.13). Based on predicted probabilities, patients were stratified into three distinct risk groups (low: P < 0.3; medium: 0.3 ≤ P ≤ 0.7; high: P > 0.7), enabling effective differentiation of SRP risk for clinical application. CONCLUSION: The integration of a low-dose parameter (V5), a novel volumetric ratio (LPR), and other prior treatment history (OT) yields a robust and parsimonious model for predicting SRP after lung SBRT. The derived three-tiered risk score offers a practical, interpretable tool that may inform individualized patient counseling and assist clinicians during treatment planning, although further prospective validation is needed.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yang X, Wang Q, Ruan C, et al. Development of a multifactorial prediction model for symptomatic radiation pneumonitis in lung cancer patients undergoing stereotactic body radiotherapy. Radiat Oncol. 2026. PMID: 42174644. doi:10.1186/s13014-026-02861-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。